MENU
+Compare
ELAB
Stock ticker: NASDAQ
AS OF
Feb 3 closing price
Price
$2.01
Change
-$4.09 (-67.05%)
Capitalization
2.38M

ELAB PMGC Holdings Inc. Forecast, Technical & Fundamental Analysis

PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation... Show more

ELAB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for ELAB with price predictions
Feb 02, 2026

ELAB sees its Stochastic Oscillator ascending out of oversold territory

On January 30, 2026, the Stochastic Oscillator for ELAB moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 25 instances where the indicator left the oversold zone. In of the 25 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on February 02, 2026. You may want to consider a long position or call options on ELAB as a result. In of 39 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ELAB just turned positive on January 07, 2026. Looking at past instances where ELAB's MACD turned positive, the stock continued to rise in of 12 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ELAB advanced for three days, in of 79 cases, the price rose further within the following month. The odds of a continued upward trend are .

ELAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ELAB entered a downward trend on January 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.281) is normal, around the industry mean (27.778). P/E Ratio (0.013) is within average values for comparable stocks, (51.342). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.892). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (1.308) is also within normal values, averaging (333.006).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ELAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ELAB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
120 Newport Center Drive
Phone
+1 866 794-4940
Employees
18
Web
https://www.elevailabs.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
H156.121.22
+0.79%
Hyatt Hotels Corp
FORTY165.68N/A
N/A
Formula Systems (1985) Ltd
NUS10.32-0.21
-1.99%
NuSkin Enterprises
FNGR1.29-0.12
-8.80%
FingerMotion
XXII6.48-0.72
-10.00%
22nd Century Group Inc.

ELAB and Stocks

Correlation & Price change

A.I.dvisor tells us that ELAB and HURA have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ELAB and HURA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAB
1D Price
Change %
ELAB100%
-40.00%
HURA - ELAB
27%
Poorly correlated
-3.03%
VTGN - ELAB
26%
Poorly correlated
+3.82%
LXRX - ELAB
25%
Poorly correlated
+7.76%
LTRN - ELAB
25%
Poorly correlated
-2.86%
MTNB - ELAB
25%
Poorly correlated
+0.45%
More